Abstract
Parsol 1789 and eusolex 8021 are two 1,3-diarylpropane-1,3-diones widely used as UV-absorbing agents in sunscreen formulations. Their chemical structures are quite similar to that of curcumin, a natural compound known to present a wide range of relevant pharmacological activities, including antifungal and anticancer activities. Such structural similarity, together with their availability and low cost sparked our interest for investigating their potential as antiproliferative and antifungal agents. Parsol and eusolex presented antiproliferative activity against eight human cancer cell lines. Promisingly, parsol was almost as active against the human lung cancer cell line NCI-ADR/RES (GI50 1.1±0.8 μg mL-1) as the positive control doxorubicin (GI50 1.7±2.1 µg mL-1). When tested for antifungal activity, parsol and eusolex showed activity comparable to that of fluconazole, the reference drug, against Paracoccidioides brasiliensis and Cryptococcus neoformans. Sporothrix schenckii was significantly more sensitive to parsol and eusolex (MIC = 16 µg mL-1, for both compounds) than fluconazole (MIC = 64 µg mL-1)
Keywords: Parsol, Eusolex, Curcumin, Antifungal, Antiproliferative and Cancer cells.
Letters in Drug Design & Discovery
Title:Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Volume: 10 Issue: 7
Author(s): Paula Aline da Silva Abranches, Esther Dias da Silva, Eduardo Vinícius Vieira Varejao, Cleide Viviane Buzanello Martins, Ana Lucia Tasca Gois Ruiz, Maria Aparecida de Resende-Stoianoff, Joao Ernesto de Carvalho, Angelo de Fatima and Sergio Antonio Fernandes
Affiliation:
Keywords: Parsol, Eusolex, Curcumin, Antifungal, Antiproliferative and Cancer cells.
Abstract: Parsol 1789 and eusolex 8021 are two 1,3-diarylpropane-1,3-diones widely used as UV-absorbing agents in sunscreen formulations. Their chemical structures are quite similar to that of curcumin, a natural compound known to present a wide range of relevant pharmacological activities, including antifungal and anticancer activities. Such structural similarity, together with their availability and low cost sparked our interest for investigating their potential as antiproliferative and antifungal agents. Parsol and eusolex presented antiproliferative activity against eight human cancer cell lines. Promisingly, parsol was almost as active against the human lung cancer cell line NCI-ADR/RES (GI50 1.1±0.8 μg mL-1) as the positive control doxorubicin (GI50 1.7±2.1 µg mL-1). When tested for antifungal activity, parsol and eusolex showed activity comparable to that of fluconazole, the reference drug, against Paracoccidioides brasiliensis and Cryptococcus neoformans. Sporothrix schenckii was significantly more sensitive to parsol and eusolex (MIC = 16 µg mL-1, for both compounds) than fluconazole (MIC = 64 µg mL-1)
Export Options
About this article
Cite this article as:
Abranches Aline da Silva Paula, Silva Dias da Esther, Varejao Vinícius Vieira Eduardo, Martins Viviane Buzanello Cleide, Ruiz Lucia Tasca Gois Ana, Resende-Stoianoff Aparecida de Maria, Carvalho Ernesto de Joao, Fatima de Angelo and Fernandes Antonio Sergio, Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents, Letters in Drug Design & Discovery 2013; 10 (7) . https://dx.doi.org/10.2174/1570180811310070014
DOI https://dx.doi.org/10.2174/1570180811310070014 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Current Chemical Biology Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets 19F: A Versatile Reporter for Non-Invasive Physiology and Pharmacology Using Magnetic Resonance
Current Medicinal Chemistry Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties
Current Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets MDM4 (MDMX) and its Transcript Variants
Current Genomics Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Induction of CYP1A1. The AhR / DRE Paradigm Transcription, Receptor Regulation, and Expanding Biological Roles
Current Drug Metabolism New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Ubiquitin Carboxyl Hydrolase L1 Significance for Human Diseases
Protein & Peptide Letters Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents